Skip to main content
    • Aa
    • Aa

A comparison of hepatitis B seroepidemiology in ten European countries

  • A. NARDONE (a1), C. G. ANASTASSOPOULOU (a2), H. THEETEN (a3), B. KRIZ (a4), I. DAVIDKIN (a5), W. THIERFELDER (a6), D. O'FLANAGAN (a7), B. BRUZZONE (a8), J. MOSSONG (a9), H. J. BOOT (a10), D. BUTUR (a11), M. SLAČIKOVÁ (a12), M. L. C. PANAIT (a11), W. HELLENBRAND (a6), H. DE MELKER (a10), Z. SOBOTOVÁ (a12), G. ICARDI (a8), N. ANDREWS (a1), R. G. PEBODY (a1), P. VAN DAMME (a3), G. KAFATOS (a1), E. MILLER (a1) and A. HATZAKIS (a2)...

To inform current and future vaccination strategies, we describe the seroepidemiology of hepatitis B virus (HBV) infection in ten representative European countries using standardized serology that allowed international comparisons. Between 1996 and 2003, national serum banks were compiled by collecting residual sera or by community sampling; sera were then tested by each country using its preferred enzyme immunoassays and testing algorithm, and assay results were standardized. Information on current and past HBV vaccination programmes in each country was also collected. Of the ten countries, six reported low levels (<3%) of antibodies against HBV core antigen (anti-HBc). Of the eight countries testing for HBV surface antigen (HBsAg), the highest prevalence was reported in Romania (5·6%) and in the remaining seven countries prevalence was <1%. Universal HBV vaccination programmes had been established in seven countries as recommended by the World Health Organization, but the seroprevalence of antibodies against HBsAg (anti-HBs) was lower than the reported vaccine coverage in three countries. Regular serological surveys to ascertain HBV status within a population, such as reported here, provide important data to assess the need for and to evaluate universal HBV vaccination programmes.

Corresponding author
*Author for correspondence: Dr A. Nardone, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK. (Email:
Hide All
1. Valsamakis A. Molecular testing in the diagnosis and management of chronic hepatitis B. Clinical Microbiology Reviews 2007; 20: 426439.
2. Roure C. Overview of epidemiology and disease burden of hepatitis B in the European region. Vaccine 1995; 13: S1821.
3. Mahoney FJ, Kane M. Hepatitis B vaccine. In Plotkin SA, Orenstein WA eds. Vaccines, 4th edn. W. B. Saunders & Co. 2004, pp. 707743.
4. van Damme P, Vorsters A. Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001. Journal of Medical Virology 2002; 67: 433439.
5. Fenner F. Candidate viral disease for elimination or eradication. Bulletin of the World Health Organization 1998; 76: S6870.
6. World Health Organization. Expanded programme on immunisation global advisory group. Weekly Epidemiological Record 1992; 3: 1116.
7. van Damme P, et al. Introducing universal hepatitis B vaccination in Europe: differences still remain between countries. Eurosurveillance 2004; 9: 6768.
8. Mortimer PP, Miller E. Commentary: antenatal screening and targeting should be sufficient in some countries. British Medical Journal 1997; 314: 10361037.
9. O'Connell T, et al. Prevalence of hepatitis B anti-core antibody in the Republic of Ireland. Epidemiology and Infection 2000; 125: 701704.
10. Pebody RG, et al. Changing epidemiology of hepatitis B infection in Finland. Scandinavian Journal of Infectious Diseases 1999; 31: 251254.
11. Hahne S, et al. Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995–2000: implications for immunisation policy. Journal of Clinical Virology 2004; 29: 211220.
12. Osborne K, Weinberg J, Miller E. The European Sero-Epidemiology Network (ESEN). Eurosurveillance 1997; 2: 9396.
13. Nardone A, Miller E. Serological surveillance of rubella in Europe: European Sero-Epidemiology Network (ESEN2). Eurosurveillance 2004; 9: 57.
14. Kafatos G, et al. The European Sero-Epidemiology Network 2: standardization of assay results for hepatitis B virus. Journal of Viral Hepatology 2007; 14: 260268.
15. Andrews NJ, et al. The European Sero-Epidemiology Network: standardizing the enzyme immunoassay results for measles, mumps and rubella. Epidemiology and Infection 2000; 125: 127141.
16. Kafatos G, Andrews N, Nardone A. Model selection methodology for inter-laboratory standardisation of antibody titres. Vaccine 2005; 23: 50225027.
17. Dominguez A, et al. Changes in the sero-epidemiology of hepatitis B infection in Catalonia, 1989–1996. Vaccine 2000; 18: 23452350.
18. Da Villa G, et al. Impact of hepatitis B vaccination in a highly endemic area of south Italy and long-term duration of anti-HBs antibody in two cohorts of vaccinated individuals. Vaccine 2007; 25: 31333136.
19. Jilg W, Schmidt M, Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. Journal of Infectious Diseases 1989; 160: 766769.
20. Gesemann M, Scheiermann N. Hepatitis B vaccine boosting among young healthy adults. Lancet 1995; 345: 395396.
21. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996; 14: 10191027.
22. Banatvala JE, Van Damme P. Hepatitis B vaccine – do we need boosters? J Viral Hepatology 2003; 10: 16.
23. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355: 561565.
24. Andrews NJ, et al. Towards measles elimination: measles susceptibility in seventeen European countries and Australia. WHO Bulletin (in press).
25. FitzSimons D, et al. Prevention and control of viral hepatitis through adolescent health programmes in Europe. Vaccine 2007; 25: 86518659.
26. Mele A, Stroffolini T, Zanetti AR. Hepatitis B in Italy: where we are ten years after the introduction of mass vaccination. Journal of Medical Virology 2002; 67: 440443.
27. Zuckerman J, Langer B. Hepatitis B vaccination in a school age population: a feasibility study. Journal of Medical Virology 2005; 75: 4754.
28. Zuckerman J, et al. Should hepatitis B vaccination be introduced into childhood immunisation programmes in northern Europe? Lancet Infectious Diseases 2007; 7: 410419.
29. Health Protection Service Centre 2008. (,2835,en). Accessed 9 April 2008.
30. Banatvala J, Van Damme P, Emiroglu N. Hepatitis B immunisation in Britain: time to change? British Medical Journal 2006; 332: 804805.
31. Thierfelder W, et al. Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998. European Journal of Epidemiology 2001; 17: 429435.
32. Gandhi RT, et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. Journal of Infectious Diseases 2005; 191: 14351441.
33. Qirbi N, Hall AJ. Epidemiology of hepatitis B virus infection in the Middle East. Eastern Mediterranean Health Journal 2001; 7: 10341045.
34. Kelly H, et al. A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia. Vaccine 2002; 20: 31303136.
35. Nardone A, et al. The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. Vaccine 2007; 25: 78667872.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *



Full text views

Total number of HTML views: 5
Total number of PDF views: 22 *
Loading metrics...

Abstract views

Total abstract views: 176 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 22nd October 2017. This data will be updated every 24 hours.